1. Home
  2. CERT vs NEO Comparison

CERT vs NEO Comparison

Compare CERT & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CERT

Certara Inc.

HOLD

Current Price

$9.45

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$12.79

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERT
NEO
Founded
2008
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Precision Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
CERT
NEO
Price
$9.45
$12.79
Analyst Decision
Buy
Buy
Analyst Count
10
9
Target Price
$12.78
$11.38
AVG Volume (30 Days)
2.0M
2.0M
Earning Date
02-25-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$415,551,000.00
$709,162,000.00
Revenue This Year
$10.75
$10.90
Revenue Next Year
$6.32
$9.85
P/E Ratio
$140.59
N/A
Revenue Growth
11.47
10.10
52 Week Low
$8.03
$4.72
52 Week High
$15.69
$15.32

Technical Indicators

Market Signals
Indicator
CERT
NEO
Relative Strength Index (RSI) 55.10 57.47
Support Level $9.06 $12.31
Resistance Level $9.45 $13.29
Average True Range (ATR) 0.31 0.64
MACD 0.06 0.01
Stochastic Oscillator 67.49 60.00

Price Performance

Historical Comparison
CERT
NEO

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: